A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma.
暂无分享,去创建一个
S Shen | G L DeNardo | K. Lamborn | G. Denardo | S. Denardo | S. Shen | D. Kukis | R. O’Donnell | D L Kukis | S J DeNardo | G. Mirick | K R Lamborn | D S Goldstein | R T O'Donnell | A Yuan | C E Carr | G R Mirick | A. Yuan | D. Goldstein | C. Carr | R. O'donnell | Catherine E. Carr
[1] J. L. Coffey,et al. Calculating dose from remaining body activity: a comparison of two methods. , 1979, Medical physics.
[2] S. Denardo,et al. Copper chelates as probes of biological systems: stable copper complexes with a macrocyclic bifunctional chelating agent. , 1985, Analytical biochemistry.
[3] A. Epstein,et al. Non-dehalogenation Mechanisms for Excretion of Radioiodine after Administration of Labeled Antibodies , 1988, The International journal of biological markers.
[4] S. Martin,et al. A phase 1a clinical trial of LYM‐1 monoclonal antibody serotherapy in patients with refractory b cell malignancies , 1989, Hematological oncology.
[5] E. W. Bradley,et al. Radiobiological comparison of external beam irradiation and radioimmunotherapy in renal cell carcinoma xenografts. , 1989, International journal of radiation oncology, biology, physics.
[6] J. Schlom,et al. Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. , 1990, Journal of the National Cancer Institute.
[7] T. Fears,et al. Non-Hodgkin's lymphoma time trends: United States and international data. , 1992, Cancer research.
[8] M. Czuczman,et al. Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] G. Denardo,et al. A comparative study of copper‐67 radiolabeling and kinetic stabilities of antibody‐macrocycle chelate conjugates , 1994, Cancer.
[10] G. Denardo,et al. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. , 1995, Cancer research.
[11] R. Levy,et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[12] G. Denardo,et al. Antibody responses to macrocycles in lymphoma. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[13] H. Speisky,et al. Liver copper storage and transport during development: implications for cytotoxicity. , 1996, The American journal of clinical nutrition.
[14] G L DeNardo,et al. Increased survival associated with radiolabeled lym‐1 therapy for non‐hodgkin's lymphoma and chronic lymphocytic leukemia , 1997, Cancer.
[15] F. Buchegger,et al. Comparison of copper-67- and iodine-125-labeled anti-CEA monoclonal antibody biodistribution in patients with colorectal tumors. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[16] G. Denardo,et al. Efficacy and toxicity of 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji). , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[17] K. Lamborn,et al. Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignancies. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[18] M. Glennie,et al. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells. , 1998, Cancer research.
[19] J. McGahan,et al. Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] G. Denardo,et al. Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study. , 1998, Anticancer research.
[21] J. McGahan,et al. Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody. , 1998, Cancer biotherapy & radiopharmaceuticals.